Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Fellowship, Endocrinology, Metabolism And Nutrition, Duke University School of Medicine 1996 - 1998
  • Resident, Internal Medicine, University of North Carolina, Chapel Hill, School of Medicine 1994 - 1996
  • Intern, Internal Medicine, University of North Carolina, Chapel Hill, School of Medicine 1993 - 1994
  • M.D., University of Virginia 1993
• 

  Duke Appointment History

  • Professor of Medicine, Medicine, Endocrinology, Metabolism, and Nutrition, Medicine 2019 - 2020
  • Associate Professor of Medicine, Medicine, Endocrinology, Metabolism, and Nutrition, Medicine 2018 - 2019
  • Associate Professor of Medicine, Medicine, Endocrinology, Metabolism, and Nutrition, Medicine 2010 - 2017
  • Assistant Professor of Medicine, Medicine, Endocrinology, Metabolism, and Nutrition, Medicine 2006 - 2010
  • Assistant Clinical Professor of Medicine, Medicine, Endocrinology, Metabolism, and Nutrition, Medicine 2002 - 2006
  • Associate in the Department of Medicine, Medicine, Endocrinology, Metabolism, and Nutrition, Medicine 1998 - 2001
• Research
• 

  Selected Grants

  • Endocrinology and Metabolism Training Program awarded by National Institutes of Health 2019 - 2024
  • EMPA-KIDNEY Trial awarded by University of Oxford 2018 - 2022
  • Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) - Microbiome Collection awarded by The George Washington University 2012 - 2021
  • Roche Diabetes Care_LOI awarded by Roche Diagnostics 2020 - 2021
  • Hostility, PTSD and Physical Health Risk Factors awarded by National Institutes of Health 2009 - 2015
• 

  Fellowships, Supported Research, & Other Grants

  • COORDINATE-Diabetes (COOrdinating CaRDIology CliNics RAndomized Trial of Interventions to Improve OutcomEs). Duke Clinical Research Institute, Duke University Medical Center awarded by Boehringer Ingelheim 2018
  • EMPA-KIDNEY. A Multicentre International Randomized Parallel Group Double-Blind Placebo-Controlled Clinical Trial of Empagliflozin Once Daily To Assess Cardio-Renal Outcomes in Patients With Chronic Kidney Disease awarded by Boehringer Ingelheim/University of Oxford 2017
  • Predictive Algorithm and Reinforcement Learning for Diabetes Management: (PEARL-DM) awarded by DCRI Innovation Grant/Duke Forge 2017
  • Consolidated Sotagliflozin Study Program (SOTA) Non-CV Outcomes awarded by Sanofi 2017
  • American Heart Association (AHA) SFRN/Duke Clinical Research Institute Heart failure Center. Project: Improving Population Health for Patients with Diabetes and Heart Failure. Duke University Medical Center, Durham, North Carolina awarded by AHA 2016
  • Advanced Clinical Trials to Test Artificial Pancreas (AP) Device Systems in Type 1 Diabetes (UC4). NIDDK Cooperative Agreement awarded by NIDDK 2016
  • Albiglutide Phase IV HARMONY Outcomes Trial Protocol GLP116174 awarded by GSK 2015
  • Vitamin D and Type 2 Diabetes Study (D2d) awarded by NIDDK 2013
  • Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Duke University Medical Center, Durham, North Carolina awarded by NIDDK 2012
  • The EXSCEL Trial. A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Exenatide Once Weekly in Patients with Type 2 Diabetes Mellitus awarded by AstraZeneca/BMS 2009
  • TECOS: A Phase III, Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus awarded by Merck 2008
• 

  External Relationships

  • American College of Cardiology
  • American Diabetes Association
  • AstraZeneca
  • Boehringer Ingelheim/Lilly alliance
  • Continuing Education Company
  • Hawthorne Effect, Inc.
  • Jaeb Center for Health Research - coordinating center for NIDDK consortium of artificial pancreas trials
  • Novo Nordisk
  • Pfizer Inc.
  • The Endocrine Society
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Nelson, Adam J., Neha J. Pagidipati, Vanita R. Aroda, Matthew A. Cavender, Jennifer B. Green, Renato D. Lopes, Hussein Al-Khalidi, et al. “Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community.” Circulation 144, no. 1 (July 6, 2021): 74–84. https://doi.org/10.1161/CIRCULATIONAHA.121.053766.
       Full Text  Link to Item
    • Goyal, Akash, Tony Schibler, Brooke Alhanti, Karen L. Hannan, Christopher B. Granger, Michael A. Blazing, Renato D. Lopes, et al. “Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials.” Jama Netw Open 4, no. 7 (July 1, 2021): e2117963. https://doi.org/10.1001/jamanetworkopen.2021.17963.
       Full Text  Link to Item
    • Marx, Nikolaus, Lars Ryden, Frank Brosius, Antonio Ceriello, Michael Cheung, Francesco Cosentino, Jennifer Green, et al. “Towards living guidelines on cardiorenal outcomes in diabetes: A pilot project of the Taskforce of the Guideline Workshop 2020.” Diabetes Res Clin Pract 177 (July 2021): 108870. https://doi.org/10.1016/j.diabres.2021.108870.
       Full Text  Link to Item
    • Green, Jennifer B. “Cardiovascular Consequences of Gestational Diabetes.” Circulation 143, no. 10 (March 9, 2021): 988–90. https://doi.org/10.1161/CIRCULATIONAHA.120.052995.
       Full Text  Link to Item
    • Nelson, Adam J., Maddalena Ardissino, Kevin Haynes, Sonali Shambhu, Zubin J. Eapen, Darren K. McGuire, Anthony Carnicelli, et al. “Gaps in Evidence-Based Therapy Use in Insured Patients in the United States With Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease.” J Am Heart Assoc 10, no. 2 (January 19, 2021): e016835. https://doi.org/10.1161/JAHA.120.016835.
       Full Text  Link to Item
    • McAlister, Finlay A., Yinggan Zheng, Cynthia M. Westerhout, John B. Buse, Eberhard Standl, Darren K. McGuire, Frans Van de Werf, et al. “Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial.” Eur J Heart Fail 22, no. 11 (November 2020): 2026–34. https://doi.org/10.1002/ejhf.1958.
       Full Text  Link to Item
    • Marx, Nikolaus, Lars Rydén, Frank Brosius, Antonio Ceriello, Michael Cheung, Francesco Cosentino, Jennifer Green, et al. “Proceedings of the Guideline Workshop 2019: Strategies for the Optimization of Guideline Processes in Diabetes, Cardiovascular Diseases, and Kidney Diseases.” Diabetes Technol Ther 22, no. 7 (July 2020): 546–52. https://doi.org/10.1089/dia.2020.0086.
       Full Text  Link to Item
    • Mather, Kieren J., Ionut Bebu, Chelsea Baker, Robert M. Cohen, Jill P. Crandall, Cyrus DeSouza, Jennifer B. Green, et al. “Prevalence of microvascular and macrovascular disease in the Glycemia Reduction Approaches in Diabetes - A Comparative Effectiveness (GRADE) Study cohort.” Diabetes Res Clin Pract 165 (July 2020): 108235. https://doi.org/10.1016/j.diabres.2020.108235.
       Full Text  Link to Item
    • Sharma, Abhinav, Jingjing Wu, Haolin Xu, Adrian Hernandez, G Michael Felker, Sana Al-Khatib, Jennifer Green, et al. “Comparative Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators in Older Heart Failure Patients With Diabetes Mellitus.” J Am Heart Assoc 9, no. 12 (June 16, 2020): e012405. https://doi.org/10.1161/JAHA.119.012405.
       Full Text  Link to Item
    • Marx, Nikolaus, Lars Rydén, Frank Brosius, Antonio Ceriello, Michael Cheung, Francesco Cosentino, Jennifer Green, et al. “Proceedings of the Guideline Workshop 2019 - Strategies for the optimization of guideline processes in diabetes, cardiovascular diseases and kidney diseases.” Diabetes Res Clin Pract 162 (April 2020): 108092. https://doi.org/10.1016/j.diabres.2020.108092.
       Full Text  Link to Item
    • Sharma, Abhinav, Neha J. Pagidipati, Robert M. Califf, Darren K. McGuire, Jennifer B. Green, Dave Demets, Jyothis Thomas George, et al. “Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.” Circulation 141, no. 10 (March 10, 2020): 843–62. https://doi.org/10.1161/CIRCULATIONAHA.119.041022.
       Full Text  Link to Item
    • De Ferrari, Gaetano M., Susanna R. Stevens, Giuseppe Ambrosio, Sergio Leonardi, Paul W. Armstrong, Jennifer B. Green, Malgorzata Wamil, Rury R. Holman, Eric D. Peterson, and Eric D. TECOS Study Group. “Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS.” Am Heart J 220 (February 2020): 82–88. https://doi.org/10.1016/j.ahj.2019.11.005.
       Full Text  Link to Item
    • Pagidipati, Neha J., Yinggan Zheng, Jennifer B. Green, Darren K. McGuire, Robert J. Mentz, Svati Shah, Pablo Aschner, et al. “Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS.” Am Heart J 219 (January 2020): 47–57. https://doi.org/10.1016/j.ahj.2019.09.016.
       Full Text  Link to Item
    • Bhatt, Ankeet S., Nancy Luo, Nicole Solomon, Neha J. Pagidipati, Giuseppe Ambrosio, Jennifer B. Green, Darren K. McGuire, et al. “International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS.” Am Heart J 218 (December 2019): 57–65. https://doi.org/10.1016/j.ahj.2019.08.016.
       Full Text  Link to Item
    • Larkin, Mary E., David M. Nathan, Ionut Bebu, Heidi Krause-Steinrauf, William H. Herman, John M. Higgins, Margaret Tiktin, et al. “Rationale and Design for a GRADE Substudy of Continuous Glucose Monitoring.” Diabetes Technol Ther 21, no. 12 (December 2019): 682–90. https://doi.org/10.1089/dia.2019.0202.
       Full Text  Link to Item
    • Shavadia, Jay S., Yinggan Zheng, Jennifer B. Green, Paul W. Armstrong, Cynthia M. Westerhout, Darren K. McGuire, Jan H. Cornel, Rury R. Holman, and Eric D. Peterson. “Associations between β-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease.” Am Heart J 218 (December 2019): 92–99. https://doi.org/10.1016/j.ahj.2019.09.013.
       Full Text  Link to Item
    • Genuth, Saul M., Helen Vlachos, Maria Mori Brooks, John P. Bantle, Bernard R. Chaitman, Jennifer Green, Sheryl F. Kelsey, et al. “BARI 2D: A Reanalysis Focusing on Cardiovascular Events.” Mayo Clin Proc 94, no. 11 (November 2019): 2249–62. https://doi.org/10.1016/j.mayocp.2019.04.015.
       Full Text  Link to Item
    • Goldstein, Sarah A., Jennifer Green, Kurt Huber, Daniel M. Wojdyla, Renato D. Lopes, John H. Alexander, Dragos Vinereanu, Lars Wallentin, Christopher B. Granger, and Sana M. Al-Khatib. “Characteristics and Outcomes of Atrial Fibrillation in Patients With Thyroid Disease (from the ARISTOTLE Trial).” Am J Cardiol 124, no. 9 (November 1, 2019): 1406–12. https://doi.org/10.1016/j.amjcard.2019.07.046.
       Full Text  Link to Item
    • Anker, Stefan D., Javed Butler, Gerasimos S. Filippatos, Waheed Jamal, Afshin Salsali, Janet Schnee, Karen Kimura, et al. “Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.” Eur J Heart Fail 21, no. 10 (October 2019): 1279–87. https://doi.org/10.1002/ejhf.1596.
       Full Text  Link to Item
    • Packer, Milton, Javed Butler, Gerasimos S. Filippatos, Waheed Jamal, Afshin Salsali, Janet Schnee, Karen Kimura, et al. “Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.” Eur J Heart Fail 21, no. 10 (October 2019): 1270–78. https://doi.org/10.1002/ejhf.1536.
       Full Text  Link to Item
    • Wang, Allen, Jennifer B. Green, Jonathan L. Halperin, and Jonathan P. Piccini. “Atrial Fibrillation and Diabetes Mellitus: JACC Review Topic of the Week.” J Am Coll Cardiol 74, no. 8 (August 27, 2019): 1107–15. https://doi.org/10.1016/j.jacc.2019.07.020.
       Full Text  Link to Item
    • Guimarães, Patrícia O., Eric D. Peterson, Susanna R. Stevens, Yuliya Lokhnygina, Jennifer B. Green, Darren K. McGuire, Rury R. Holman, and Renato D. Lopes. “Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes.” Int J Cardiol 289 (August 15, 2019): 58–62. https://doi.org/10.1016/j.ijcard.2019.04.085.
       Full Text  Link to Item
    • Standl, Eberhard, Jennifer B. Green, Rury R. Holman, and Rury R. TECOS Study Group. “Comment on Davis et al. Effects of Severe Hypoglycemia on Cardiovascular Outcomes and Death in the Veterans Affairs Diabetes Trial. Diabetes Care 2019;42:157-163.” Diabetes Care 42, no. 6 (June 2019): e95. https://doi.org/10.2337/dc18-2597.
       Full Text  Link to Item
    • Montvida, O., J. B. Green, J. Atherton, and S. K. Paul. “Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes.” Diabet Med 36, no. 4 (April 2019): 491–98. https://doi.org/10.1111/dme.13835.
       Full Text  Link to Item
    • Wittbrodt, Eric T., James M. Eudicone, Kelly F. Bell, Devin M. Enhoffer, Keith Latham, and Jennifer B. Green. “Authors' reply to "Comment on generalizability of GLP-1 RA CVOTs in US T2D population".” Am J Manag Care 25, no. 4 (April 2019): 171–72.
       Link to Item
    • Fanaroff, Alexander C., Robert Clare, Karen S. Pieper, Kenneth W. Mahaffey, Chiara Melloni, Jennifer B. Green, John H. Alexander, et al. “Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials.” Circulation 139, no. 7 (February 12, 2019): 863–73. https://doi.org/10.1161/CIRCULATIONAHA.118.037202.
       Full Text  Link to Item
    • McHugh, Kelly, Adam D. DeVore, Jingjing Wu, Roland A. Matsouaka, Gregg C. Fonarow, Paul A. Heidenreich, Clyde W. Yancy, Jennifer B. Green, Natasha Altman, and Adrian F. Hernandez. “Heart Failure With Preserved Ejection Fraction and Diabetes: JACC State-of-the-Art Review.” J Am Coll Cardiol 73, no. 5 (February 12, 2019): 602–11. https://doi.org/10.1016/j.jacc.2018.11.033.
       Full Text  Link to Item
    • Bethel, M Angelyn, Samuel S. Engel, Susanna R. Stevens, Yuliya Lokhnygina, Jie Ding, Robert G. Josse, Michael Alvarsson, et al. “Progression of glucose-lowering diabetes therapy in TECOS.” Endocrinol Diabetes Metab 2, no. 1 (January 2019): e00053. https://doi.org/10.1002/edm2.53.
       Full Text  Link to Item
    • Herrington, William G., David Preiss, Richard Haynes, Maximilian von Eynatten, Natalie Staplin, Sibylle J. Hauske, Jyothis T. George, et al. “The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study.” Clin Kidney J 11, no. 6 (December 2018): 749–61. https://doi.org/10.1093/ckj/sfy090.
       Full Text  Link to Item
    • Hernandez, Adrian F., Jennifer B. Green, Salim Janmohamed, Ralph B. D’Agostino, Christopher B. Granger, Nigel P. Jones, Lawrence A. Leiter, et al. “Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.” Lancet 392, no. 10157 (October 27, 2018): 1519–29. https://doi.org/10.1016/S0140-6736(18)32261-X.
       Full Text  Link to Item
    • Alfredsson, Joakim, Jennifer B. Green, Susanna R. Stevens, Shelby D. Reed, Paul W. Armstrong, M. Angelyn Bethel, Samuel S. Engel, et al. “Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS.” Diabetes Obes Metab 20, no. 10 (October 2018): 2379–88. https://doi.org/10.1111/dom.13377.
       Full Text  Link to Item
    • DeVore, Adam D., and Jennifer B. Green. “Preventing Heart Failure in Diabetes: Glycemic Targets or Class Effect?” Jacc Heart Fail 6, no. 10 (October 2018): 831–32. https://doi.org/10.1016/j.jchf.2018.07.014.
       Full Text  Link to Item
    • Green, Jennifer B., Adrian F. Hernandez, Ralph B. D’Agostino, Chris B. Granger, Salim Janmohamed, Nigel P. Jones, Lawrence A. Leiter, et al. “Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics.” Am Heart J 203 (September 2018): 30–38. https://doi.org/10.1016/j.ahj.2018.03.030.
       Full Text  Link to Item
    • McHugh, Kelly R., Adam D. DeVore, Robert J. Mentz, Daniel Edmonston, Jennifer B. Green, and Adrian F. Hernandez. “The emerging role of novel antihyperglycemic agents in the treatment of heart failure and diabetes: A focus on cardiorenal outcomes.” Clin Cardiol 41, no. 9 (September 2018): 1259–67. https://doi.org/10.1002/clc.23054.
       Full Text  Link to Item
    • Reed, Shelby D., Yanhong Li, Jose Leal, Larry Radican, Amanda I. Adler, Joakim Alfredsson, John B. Buse, et al. “Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).” Diabetes Obes Metab 20, no. 7 (July 2018): 1732–39. https://doi.org/10.1111/dom.13292.
       Full Text  Link to Item
    • Wittbrodt, E. T., J. M. Eudicone, K. F. Bell, D. M. Enhoffer, K. Latham, and J. B. Green. “Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population.” The American Journal of Managed Care 24, no. 8 (April 1, 2018): S146–55.
    • Wittbrodt, E. T., J. M. Eudicone, K. F. Bell, D. M. Enhoffer, K. Latham, and J. B. Green. “Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population.” The American Journal of Managed Care 24, no. 8 (April 1, 2018): S138–45.
    • Wittbrodt, Eric T., James M. Eudicone, Kelly F. Bell, Devin M. Enhoffer, Keith Latham, and Jennifer B. Green. “Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population.” Am J Manag Care 24, no. 8 Suppl (April 2018): S138–45.
       Link to Item
    • Wittbrodt, Eric T., James M. Eudicone, Kelly F. Bell, Devin M. Enhoffer, Keith Latham, and Jennifer B. Green. “Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population.” Am J Manag Care 24, no. 8 Suppl (April 2018): S146–55.
       Link to Item
    • Standl, Eberhard, Susanna R. Stevens, Paul W. Armstrong, John B. Buse, Juliana C. N. Chan, Jennifer B. Green, John M. Lachin, et al. “Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype.” Diabetes Care 41, no. 3 (March 2018): 596–603. https://doi.org/10.2337/dc17-1778.
       Full Text  Link to Item
    • Cefalu, William T., Sanjay Kaul, Hertzel C. Gerstein, Rury R. Holman, Bernard Zinman, Jay S. Skyler, Jennifer B. Green, et al. “Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum.” Diabetes Care 41, no. 1 (January 2018): 14–31. https://doi.org/10.2337/dci17-0057.
       Full Text  Link to Item
    • Sharma, Abhinav, Jennifer B. Green, Allison Dunning, Yuliya Lokhnygina, Sana M. Al-Khatib, Renato D. Lopes, John B. Buse, et al. “Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial.” Diabetes Care 40, no. 12 (December 2017): 1763–70. https://doi.org/10.2337/dc17-1091.
       Full Text  Link to Item
    • Butler, Javed, Carine E. Hamo, Gerasimos Filippatos, Stuart J. Pocock, Richard A. Bernstein, Martina Brueckmann, Alfred K. Cheung, et al. “The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors.” Eur J Heart Fail 19, no. 11 (November 2017): 1390–1400. https://doi.org/10.1002/ejhf.933.
       Full Text  Link to Item
    • Navar, Ann Marie, Dianne S. Gallup, Yuliya Lokhnygina, Jennifer B. Green, Darren K. McGuire, Paul W. Armstrong, John B. Buse, et al. “Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events: Global Results From the Trial Evaluating Cardiovascular Outcomes With Sitagliptin.” Hypertension 70, no. 5 (November 2017): 907–14. https://doi.org/10.1161/HYPERTENSIONAHA.117.09482.
       Full Text  Link to Item
    • Pagidipati, Neha J., Ann Marie Navar, Karen S. Pieper, Jennifer B. Green, M Angelyn Bethel, Paul W. Armstrong, Robert G. Josse, et al. “Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin).” Circulation 136, no. 13 (September 26, 2017): 1193–1203. https://doi.org/10.1161/CIRCULATIONAHA.117.027252.
       Full Text  Link to Item
    • Herbst, Rebecca, Wilburn Bolton, Afreen Shariff, and Jennifer B. Green. “Cardiovascular Outcome Trial Update in Diabetes: New Evidence, Remaining Questions.” Curr Diab Rep 17, no. 9 (September 2017): 67. https://doi.org/10.1007/s11892-017-0898-8.
       Full Text  Link to Item
    • Bethel, M Angelyn, Samuel S. Engel, Jennifer B. Green, Zhen Huang, Robert G. Josse, Keith D. Kaufman, Eberhard Standl, et al. “Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).” Diabetes Care 40, no. 4 (April 2017): 494–501. https://doi.org/10.2337/dc16-1135.
       Full Text
    • Spratt, Susan E., Katherine Pereira, Bradi B. Granger, Bryan C. Batch, Matthew Phelan, Michael Pencina, Marie Lynn Miranda, et al. “Assessing electronic health record phenotypes against gold-standard diagnostic criteria for diabetes mellitus.” J Am Med Inform Assoc 24, no. e1 (April 1, 2017): e121–28. https://doi.org/10.1093/jamia/ocw123.
       Full Text  Link to Item
    • Buse, John B., M Angelyn Bethel, Jennifer B. Green, Susanna R. Stevens, Yuliya Lokhnygina, Pablo Aschner, Carlos Raffo Grado, et al. “Pancreatic Safety of Sitagliptin in the TECOS Study.” Diabetes Care 40, no. 2 (February 2017): 164–70. https://doi.org/10.2337/dc15-2780.
       Full Text  Link to Item
    • Ikeno, Fumiaki, Maria Mori Brooks, Kaori Nakagawa, Min-Kyu Kim, Hideaki Kaneda, Yoshiaki Mitsutake, Helen A. Vlachos, et al. “SYNTAX Score and Long-Term Outcomes: The BARI-2D Trial.” J Am Coll Cardiol 69, no. 4 (January 31, 2017): 395–403. https://doi.org/10.1016/j.jacc.2016.10.067.
       Full Text  Link to Item
    • Josse, Robert G., Sumit R. Majumdar, Yinggan Zheng, Amanda Adler, M Angelyn Bethel, John B. Buse, Jennifer B. Green, et al. “Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial.” Diabetes Obes Metab 19, no. 1 (January 2017): 78–86. https://doi.org/10.1111/dom.12786.
       Full Text  Link to Item
    • Cooper, Lauren B., Xiaojuan Mi, Robert J. Mentz, Jennifer B. Green, Kevin J. Anstrom, Adrian F. Hernandez, and Lesley H. Curtis. “Management of newly treated diabetes in Medicare beneficiaries with and without heart failure.” Clin Cardiol 40, no. 1 (January 2017): 38–45. https://doi.org/10.1002/clc.22603.
       Full Text  Link to Item
    • Coch, R. W., and J. B. Green. “Current cardiovascular outcomes trials in type 2 diabetes: Perspectives and insight.” Nutr Metab Cardiovasc Dis 26, no. 9 (September 2016): 767–72. https://doi.org/10.1016/j.numecd.2016.06.004.
       Full Text  Link to Item
    • McGuire, Darren K., Frans Van de Werf, Paul W. Armstrong, Eberhard Standl, Joerg Koglin, Jennifer B. Green, M Angelyn Bethel, et al. “Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.” Jama Cardiol 1, no. 2 (May 1, 2016): 126–35. https://doi.org/10.1001/jamacardio.2016.0103.
       Full Text  Link to Item
    • Barnard, Karen, Wanda C. Lakey, Bryan C. Batch, Karen Chiswell, Asba Tasneem, and Jennifer B. Green. “Recent Clinical Trials in Osteoporosis: A Firm Foundation or Falling Short?” Plos One 11, no. 5 (2016): e0156068. https://doi.org/10.1371/journal.pone.0156068.
       Full Text  Open Access Copy  Link to Item
    • Espeland, Mark A., Jeffery Probstfield, Donald Hire, J Bruce Redmon, Gregory W. Evans, Mace Coday, Cora E. Lewis, et al. “Systolic Blood Pressure Control Among Individuals With Type 2 Diabetes: A Comparative Effectiveness Analysis of Three Interventions.” Am J Hypertens 28, no. 8 (August 2015): 995–1009. https://doi.org/10.1093/ajh/hpu292.
       Full Text  Link to Item
    • Green, Jennifer B., M Angelyn Bethel, Paul W. Armstrong, John B. Buse, Samuel S. Engel, Jyotsna Garg, Robert Josse, et al. “Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.” N Engl J Med 373, no. 3 (July 16, 2015): 232–42. https://doi.org/10.1056/NEJMoa1501352.
       Full Text  Link to Item
    • Green, Jennifer B. “Update in endocrinology: evidence published in 2014.” Ann Intern Med 162, no. 9 (May 5, 2015): W91–95. https://doi.org/10.7326/M15-0153.
       Full Text  Link to Item
    • Bethel, M. A., J. B. Green, J. Milton, A. Tajar, S. S. Engel, R. M. Califf, R. R. Holman, and R. R. TECOS Executive Committee. “Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).” Diabetes Obes Metab 17, no. 4 (April 2015): 395–402. https://doi.org/10.1111/dom.12441.
       Full Text  Link to Item
    • Koshizaka, Masaya, Renato D. Lopes, Eric M. Reyes, C Michael Gibson, Phillip J. Schulte, Gail E. Hafley, Adrian F. Hernandez, et al. “Long-term clinical and angiographic outcomes in patients with diabetes undergoing coronary artery bypass graft surgery: results from the Project of Ex-vivo Vein Graft Engineering via Transfection IV trial.” Am Heart J 169, no. 1 (January 2015): 175–84. https://doi.org/10.1016/j.ahj.2014.10.013.
       Full Text  Link to Item
    • Magee, M. F., J. E. Tamis-Holland, J. Lu, V. A. Bittner, M. M. Brooks, N. Lopes, A. K. Jacobs, et al. “Sex, prescribing practices and guideline recommended, blood pressure, and LDL cholesterol targets at baseline in the BARI 2D trial.” International Journal of Endocrinology 2015 (January 1, 2015). https://doi.org/10.1155/2015/610239.
       Full Text
    • Green, Jennifer B. “Understanding the type 2 diabetes mellitus and cardiovascular disease risk paradox.” Postgrad Med 126, no. 3 (May 2014): 190–204. https://doi.org/10.3810/pgm.2014.05.2767.
       Full Text  Link to Item
    • Ismail-Beigi, Faramarz, Manuel S. Lombardero, Jorge Escobedo, Saul Genuth, Jennifer Green, Elaine Massaro, Arshag D. Mooradian, et al. “Determinants of successful glycemic control among participants in the BARI 2D trial: a post-hoc analysis.” J Diabetes Complications 28, no. 1 (January 2014): 101–9. https://doi.org/10.1016/j.jdiacomp.2013.01.006.
       Full Text  Link to Item
    • Green, Jennifer B., M Angelyn Bethel, Sanjoy K. Paul, Arne Ring, Keith D. Kaufman, Deborah R. Shapiro, Robert M. Califf, and Rury R. Holman. “Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.” Am Heart J 166, no. 6 (December 2013): 983-989.e7. https://doi.org/10.1016/j.ahj.2013.09.003.
       Full Text  Link to Item
    • Povsic, Thomas J., Richard Sloane, Jiying Zhou, Carl F. Pieper, Megan P. Pearson, Eric D. Peterson, Jennifer B. Green, Harvey J. Cohen, and Miriam C. Morey. “Lower levels of circulating progenitor cells are associated with low physical function and performance in elderly men with impaired glucose tolerance: a pilot substudy from the VA Enhanced Fitness trial.” J Gerontol a Biol Sci Med Sci 68, no. 12 (December 2013): 1559–66. https://doi.org/10.1093/gerona/glt067.
       Full Text  Link to Item
    • Povsic, Thomas J., Richard Sloane, Jennifer B. Green, Jiying Zhou, Carl F. Pieper, Megan P. Pearson, Eric D. Peterson, Harvey J. Cohen, and Miriam C. Morey. “Depletion of circulating progenitor cells precedes overt diabetes: a substudy from the VA enhanced fitness trial.” J Diabetes Complications 27, no. 6 (November 2013): 633–36. https://doi.org/10.1016/j.jdiacomp.2013.08.004.
       Full Text  Link to Item
    • Pop-Busui, Rodica, Jiang Lu, Maria Mori Brooks, Stewart Albert, Andrew D. Althouse, Jorge Escobedo, Jenifer Green, et al. “Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort.” Diabetes Care 36, no. 10 (October 2013): 3208–15. https://doi.org/10.2337/dc13-0012.
       Full Text  Link to Item
    • Green, Jennifer B. “Diabetes trials: is an ounce of prevention enough?” Expert Rev Endocrinol Metab 8, no. 5 (September 2013): 419–21. https://doi.org/10.1586/17446651.2013.827382.
       Full Text  Link to Item
    • Lakey, W. C., K. Barnard, B. C. Batch, K. Chiswell, A. Tasneem, and J. B. Green. “Are current clinical trials in diabetes addressing important issues in diabetes care?” Diabetologia 56, no. 6 (June 2013): 1226–35. https://doi.org/10.1007/s00125-013-2890-4.
       Full Text  Link to Item
    • Green, J. B., W. Lakey, K. Barnard, B. Batch, M. Bethel, K. Chiswell, and A. Tasneem. “State of diabetes-related trials in the clinicaltrials.gov dataset.” Diabetologia 55 (October 1, 2012): S90–91.
       Link to Item
    • Morey, Miriam C., Carl F. Pieper, David E. Edelman, William S. Yancy, Jennifer B. Green, Helen Lum, Matthew J. Peterson, et al. “Enhanced fitness: a randomized controlled trial of the effects of home-based physical activity counseling on glycemic control in older adults with prediabetes mellitus.” J Am Geriatr Soc 60, no. 9 (September 2012): 1655–62. https://doi.org/10.1111/j.1532-5415.2012.04119.x.
       Full Text  Link to Item
    • Green, Jennifer B. “The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety.” Postgrad Med 124, no. 4 (July 2012): 54–61. https://doi.org/10.3810/pgm.2012.07.2566.
       Full Text  Link to Item
    • Schwartz, Ann V., Karen L. Margolis, Deborah E. Sellmeyer, Eric Vittinghoff, Walter T. Ambrosius, Denise E. Bonds, Robert G. Josse, et al. “Intensive glycemic control is not associated with fractures or falls in the ACCORD randomized trial.” Diabetes Care 35, no. 7 (July 2012): 1525–31. https://doi.org/10.2337/dc11-2184.
       Full Text  Link to Item
    • Stiles, Monica C., Elizabeth R. Seaquist, Jean Francois Yale, Jennifer B. Green, Lois Anne Katz, Sarah Kempainen, Laney S. Light, Patricia V. Pepper, Zhu-Ming Zhang, and Elsayed Z. Soliman. “Is silent myocardial infarction more common in women with type 2 diabetes than in men?” J Diabetes Complications 26, no. 2 (March 2012): 118–22. https://doi.org/10.1016/j.jdiacomp.2012.02.002.
       Full Text  Link to Item
    • Koshizaka, Masaya, Jennifer B. Green, and John H. Alexander. “Glycemic management in diabetes and the associated cardiovascular risk: are we helping or hurting our patients?” Circ J 76, no. 7 (2012): 1572–80. https://doi.org/10.1253/circj.cj-12-0428.
       Full Text  Link to Item
    • Hall, Katherine S., Carl F. Pieper, David E. Edelman, William S. Yancy, Jennifer B. Green, Helen Lum, Matthew J. Peterson, et al. “Lessons learned when innovations go awry: a baseline description of a behavioral trial-the Enhancing Fitness in Older Overweight Veterans with Impaired Fasting Glucose study.” Transl Behav Med 1, no. 4 (November 2011): 573–87. https://doi.org/10.1007/s13142-011-0075-6.
       Full Text  Link to Item
    • Buse, John B., George Dailey, Andrew A. Ahmann, Richard M. Bergenstal, Jennifer B. Green, Tim Peoples, Robert J. Tanenberg, and Qingqing Yang. “Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy: the STAR 3 experience.” Diabetes Technol Ther 13, no. 6 (June 2011): 601–6. https://doi.org/10.1089/dia.2010.0225.
       Full Text  Link to Item
    • Chen, Louis C., and Jennifer B. Green. “First reported case of unilateral Graves' disease in the left lobe of a bilobar thyroid gland.” Thyroid 21, no. 6 (June 2011): 683–86. https://doi.org/10.1089/thy.2010.0343.
       Full Text  Link to Item
    • Jiang, Wei, Shelby Ladd, Carolyn Martsberger, Mark Feinglos, Susan E. Spratt, Maragatha Kuchibhatla, Jennifer Green, and Ranga Krishnan. “Effects of pregabalin on heart rate variability in patients with painful diabetic neuropathy.” J Clin Psychopharmacol 31, no. 2 (April 2011): 207–13. https://doi.org/10.1097/JCP.0b013e31820f4f57.
       Full Text  Link to Item
    • Barnard, Karen, Mary Elizabeth Cox, and Jennifer B. Green. “Clinical utility of fixed combinations of sitagliptin-metformin in treatment of type 2 diabetes.” Diabetes Metab Syndr Obes 3 (October 27, 2010): 363–72. https://doi.org/10.2147/DMSOTT.S10195.
       Full Text  Link to Item
    • Cox, Mary Elizabeth, Jennifer Rowell, Leonor Corsino, and Jennifer B. Green. “Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy.” Drug Healthc Patient Saf 2 (2010): 7–19. https://doi.org/10.2147/dhps.s6270.
       Full Text  Link to Item
    • Corsino, Leonor, Mary Elizabeth Cox, Jennifer Rowel, and Jennifer B. Green. “Present and Prospective Pharmacotherapy for the Management of Patients with Type 2 Diabetes.” Clin Med Ther 1 (August 27, 2009): 1103–19. https://doi.org/10.4137/cmt.s2109.
       Full Text  Link to Item
    • Pop-Busui, Rodica, Manuel Lombardero, Victor Lavis, Alan Forker, Jennifer Green, Mary Korytkowski, Burton E. Sobel, Teresa L. Z. Jones, and Teresa L. Z. BARI 2D Study Group. “Relation of severe coronary artery narrowing to insulin or thiazolidinedione use in patients with type 2 diabetes mellitus (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes Study).” Am J Cardiol 104, no. 1 (July 1, 2009): 52–58. https://doi.org/10.1016/j.amjcard.2009.02.046.
       Full Text  Link to Item
    • Gerstein, H. C., M. E. Miller, R. P. Byington, D. C. Goff, J. T. Bigger, J. B. Buse, W. C. Cushman, et al. “Effects of intensive glucose lowering in type 2 diabetes.” New England Journal of Medicine 358, no. 24 (June 12, 2008): 2545–59. https://doi.org/10.1056/NEJMoa0802743.
       Full Text
    • Green, Jennifer, and Mark Feinglos. “New combination treatments in the management of diabetes: focus on sitagliptin-metformin.” Vasc Health Risk Manag 4, no. 4 (2008): 743–51. https://doi.org/10.2147/vhrm.s3105.
       Full Text  Link to Item
    • Green, Jennifer B., and Mark N. Feinglos. “Exenatide and rimonabant: new treatments that may be useful in the management of diabetes and obesity.” Curr Diab Rep 7, no. 5 (October 2007): 369–75. https://doi.org/10.1007/s11892-007-0060-0.
       Full Text  Link to Item
    • Green, J., and M. Feinglos. “Update on type 2 diabetes mellitus: understanding changes in the diabetes treatment paradigm.” Int J Clin Pract Suppl, no. 154 (August 2007): 3–11. https://doi.org/10.1111/j.1742-1241.2007.01438.x.
       Full Text  Link to Item
    • Buse, J. B., W. T. Friedewald, J. T. Bigger, R. P. Byington, W. C. Cushman, S. Genuth, H. C. Gerstein, et al. “Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: Design and methods.” American Journal of Cardiology 99, no. 12 (June 18, 2007). https://doi.org/10.1016/j.amjcard.2007.03.003.
       Full Text
    • Green, Jennifer B., and Mark N. Feinglos. “Are sulfonylureas passé?” Curr Diab Rep 6, no. 5 (November 2006): 373–77. https://doi.org/10.1007/s11892-006-0008-9.
       Full Text  Link to Item
    • Weber, T. J., J. B. Green, H. Chow, A. Spitz, and G. S. Wagner. “How bone density testing influenced osteoporosis treatment in a community hospital.” N C Med J 61, no. 6 (November 2000): 321–24.
       Link to Item

  • Book Sections

    • Green, J. B. “Disorders of monosaccharide metabolism.” In Garner and Klintworth’s Pathobiology of Ocular Disease Part B, Third Edition, 1005–18, 2007.

  • Conference Papers

    • Shavadia, Jay, Yinggan Zheng, Jennifer B. Green, Paul Armstrong, Cynthia Westerhout, Darren McGuire, Matthew Roe, J. H. Cornel, Rury Holman, and Eric D. Peterson. “ASSOCIATIONS BETWEEN BETA-BLOCKER THERAPY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIABETES AND ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: INSIGHTS FROM THE TECOS STUDY.” In Journal of the American College of Cardiology, 73:138–138. Elsevier BV, 2019. https://doi.org/10.1016/s0735-1097(19)30746-6.
       Full Text
    • De Ferrari, G. M., S. R. Stevens, G. Ambrosio, S. Leonardi, D. K. McGuire, P. W. Armstrong, J. B. Green, M. A. Bethel, R. R. Holman, and E. D. Peterson. “LDL-C treatment patterns and associated outcomes in patients with type 2 diabetes and CVD: insights from TECOS.” In European Heart Journal, 39:399–400. OXFORD UNIV PRESS, 2018.
       Link to Item
    • McHugh, Kelly, JingJing Wu, Roland A. Matsouaka, Adam D. DeVore, Gregg C. Fonarow, Paul A. Heidenreich, Clyde W. Yancy, Jennifer B. Green, Natasha Altman, and Adrian F. Hernandez. “Diabetes is Associated with Worse In-Hospital and 30-Day Post-Discharge Morbidity in Patients with Heart Failure with Preserved Ejection Fraction: Findings from the Get With The Guidelines Heart Failure Registry.” In Journal of Cardiac Failure, 24:S92–S92. Elsevier BV, 2018. https://doi.org/10.1016/j.cardfail.2018.07.358.
       Full Text
    • Sharma, A., Y. Zheng, J. A. Ezekowitz, C. M. Westerhout, S. G. Goodman, P. W. Armstrong, J. B. Buse, et al. “Cluster analysis of cardiovascular risk phenotypes in patients with type 2 diabetes and established atherosclerotic cardiovascular disease: a potential approach to precision medicine.” In European Heart Journal, 39:871–871. OXFORD UNIV PRESS, 2018.
       Link to Item
    • Engel, S. S., M. A. Bethel, J. Garg, S. R. Stevens, Y. Lokhnygina, R. G. Josse, J. B. Green, E. D. Peterson, and R. R. Holman. “Time to insulin in the Trial Evaluating Cardiovascular Outomes with Sitagliptin (TECOS).” In Diabetologia, 60:S3–S3. SPRINGER, 2017.
       Link to Item
    • Gray, A. M., J. Leal, S. D. Reed, Y. Li, F. Graham, J. B. Green, K. D. Kaufman, et al. “Resource use and UK-perspective costs in patients with type 2 diabetes during the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).” In Diabetologia, 60:S357–S357. SPRINGER, 2017.
       Link to Item
    • Paul, S., J. B. Green, J. Atherton, and O. Montvida. “Risk of pancreatic diseases by second-line anti diabetes drug class: real world based evidence.” In Diabetologia, 60:S69–70. SPRINGER, 2017.
       Link to Item
    • Pagidipati, N., Y. Zheng, J. B. Green, D. K. Mcguire, R. J. Mentz, S. Shah, P. Aschner, et al. “The association between obesity, diabetes control, and cardiovascular outcomes: insights from the TECOS trial.” In European Heart Journal, 38:608–608. OXFORD UNIV PRESS, 2017.
       Link to Item
    • Green, J. B., J. Alfredsson, S. R. Stevens, S. D. Reed, D. K. McGuire, P. W. Armstrong, S. S. Engel, et al. “Sex differences in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).” In Diabetologia, 59:S544–45. SPRINGER, 2016.
       Link to Item
    • Josse, R. G., S. R. Majumdar, Y. Zheng, J. B. Buse, J. B. Green, K. D. Kaufman, E. D. Peterson, R. R. Holman, and P. W. Armstrong. “Sitagliptin and risk of fractures in type 2 diabetes: results from the TECOS trial.” In Diabetologia, 59:S372–S372. SPRINGER, 2016.
       Link to Item
    • Lee, S. W., J. B. Welsh, J. B. Green, C. Joyce, W. V. Tamborlane, and F. R. Kaufman. “Successful transitions from MDI therapy to sensor-augmented pump therapy in the STAR 3 study: system settings and behaviours.” In Diabetologia, 54:S395–96. SPRINGER, 2011.
       Link to Item
    • Calles-Escandon, J., L. Light, L. Lovato, A. Getaneh, D. Simmons, J. Kirk, D. Bonds, et al. “Glycaemia management of minority participants in ACCORD.” In Diabetologia, 53:S19–S19. SPRINGER, 2010.
       Link to Item
    • Green, J. B., A. Ahmann, R. M. Bergenstal, G. Dailey, R. Tanenberg, and J. B. Buse. “Glucose control in adults during a 1-year randomised controlled trial comparing sensor-augmented pump therapy and multiple daily injection therapy: STAR 3 study.” In Diabetologia, 53:S24–S24. SPRINGER, 2010.
       Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.